Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities

CMAJ

Volumn 186, Issue 12, 2014, Pages E449-E456

  Halava, Heli ^a   Korhonen, Maarit Jaana ^a   Huupponen, Risto ^a,b   Setoguchi, Soko ^c   Pentti, Jaana ^d   Kivimäki, Mika ^e   Vahtera, Jussi ^a,b,d  

^a Department of Public Health ^*  (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLUSTER ANALYSIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE REGISTRY; DRINKING BEHAVIOR; DYSLIPIDEMIA; EMPLOYEE; FEMALE; FINN (CITIZEN); HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PREDICTION; PRESCRIPTION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SMOKING; TREATMENT DURATION; YOUNG ADULT; FINLAND; FOLLOW UP; MEDICATION COMPLIANCE; REGISTER; STATISTICAL MODEL; STATISTICS;

ADULT; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; FINLAND; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84907164563     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.131807     Document Type: Article

References (41)

1. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34:2940-8.
2. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 2013;15:291-8.
3. Mann DM, Woodward M, Muntner P, et al. Predictors of non - adherence to statins: a systematic review and meta-analysis. Ann Pharmacother 2010;44:1410-21.
4. Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol 2012;28:574-80.
5. Latry P, Molimard M, Begaud B, et al. How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database. Eur J Clin Pharmacol 2010;66:743-8.
6. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009; 119: 2051-7.
7. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166: 348-54.
8. Patrick AR, Shrank WH, Glynn RJ, et al. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health 2011;14:513-20.
9. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105:2341-6.
10. Kopjar B, Sales AEB, Piñeros SL, et al. Adherence with statin therapy in secondary prevention of coronary heart disease in Veterans Administration male population. Am J Cardiol 2003;92: 1106-8.
11. Yang CC, Jick SS, Testa MA. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin Pharmacol 2003; 56:84-91.
12. Di Martino M, Degli Esposti L, Ruffo P, et al. Underuse of lipidlowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol 2005;61: 225-30.
13. Carey IM, DeWilde S, Shah SM, et al. Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment? Nutr Metab Cardiovasc Dis 2012;22:400-8.
14. Warren JR, Falster MO, Fox D, et al. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf 2013;22:1298-307.
15. Bryson CL, Au DH, Sun H, et al. Alcohol screening scores and medication nonadherence. Ann Intern Med 2008;149:795-804.
16. Natarajan N, Putnam RW, Yip AM, et al. Family practice patients' adherence to statin medications. Can Fam Physician 2007; 53: 2144-5.
17. Donnelly LA, Doney ASF, Morrist AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med 2008;25:850-5.
18. Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67.
19. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
20. Vahtera J, Laine S, Virtanen M, et al. Employee control over working times and risk of cause-specific disability pension: the Finnish Public Sector Study. Occup Environ Med 2010;67:479-85.
21. Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94.
22. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9.
23. WHO Collaborating Centre for Drug Statistics Methodology. Use of ATC/DDD. Available: www.whocc.no/use-of-atc-ddd/ (accessed 2014 June 2).
24. Lesén E, Sandstrom TZ, Carlsten A, et al. A comparison of two methods for estimating refill adherence to statins in Sweden: the RARE project. Pharmacoepidemiol Drug Saf 2011;20:1073-9.
25. Kivimäki M, Lawlor DA, Davey Smith G, et al. Socioeconomic position, co-occurrence of behavior-related risk factors, and coronary heart disease: the Finnish Public Sector study. Am J Public Health 2007;97:874-9.
26. Halonen JI, Kivimäki M, Virtanen M, et al. Living in proximity of a bar and risky alcohol behaviours: a longitudinal study. Addiction 2013;108:320-8.
27. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 [published errata in Lancet 2013;381:1276 and 2013;381:628]. Lancet 2012;380:2224-60.
28. Kivimäki M, Batty GD, Hamer M, et al. Influence of retirement on nonadherence to medication for hypertension and diabetes. CMAJ 2013;185:E784-90.
29. Calip GS, Boudreau DM, Loggers ET. Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat 2013;138:225-33.
30. Sjösten N, Nabi H, Westerlund H, et al. Effect of depression onset on adherence to medication among hypertensive patients: a longitudinal modelling study. J Hypertens 2013;31:1477-84, discussion 1484.
31. Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med 2011;26:1175-82.
32. Gadkari AS, McHorney C. Unintentional non-adherence to chronic prescription medications: How unintentional is it really? BMC Health Serv Res 2012;12:98.
33. Official Statistics of Finland (OSF): Official Statistics of Finland [e-publication]. Helsinki (Finland): Advisory Board of OSF. Available: www.stat.fi/meta/svt/index-en.html (accessed 2014 Feb. 4).
34. Helin-Salmivaara A, Korhonen MJ, Alanen T, et al. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland. J Clin Pharm Ther 2012;37:58-64.
35. Helin-Salmivaara A, Lavikainen PT, Korhonen MJ, et al. Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care 2010;16: 116-22.
36. Berglund E, Lytsy P, Westerling R. Adherence to and beliefs in lipid-lowering medical treatments: a structural equation modeling approach including the necessity-concern framework. Patient Educ Couns 2013;91:105-12.
37. Mann DM, Allegrante JP, Natarajan S, et al. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007; 21:311-6.
38. Wills AK, Lawlor DA, Matthews FE, et al. Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts. PLoS Med 2011;8:e1000440.
39. Fendrich M, Mackesy-Amiti ME, Johnson TP, et al. Tobaccoreporting validity in an epidemiological drug-use survey. Addict Behav 2005;30:175-81.
40. Ekholm O, Strandberg-Larsen K, Gronbaek M. Influence of the recall period on a beverage-specific weekly drinking measure for alcohol intake. Eur J Clin Nutr 2011;65:520-5.
41. Hempler NF, Krasnik A, Pisinger C, et al. The relationship between changes in health behaviour and initiation of lipid-lowering and antihypertensive medications in individuals at high risk of ischaemic heart disease. BMC Public Health 2012;12: 626-33.